Discover how Circular Genomics' innovative circular RNA biomarker platform is revolutionizing early detection of Alzheimer's Disease at CTAD 2025.

Circular Genomics has been awarded a $250K investment from the Alzheimer's Drug Discovery Foundation to advance blood-based circRNA biomarker tests for early Alzheimer's detection.

Discover how Circular Genomics and Altoida's partnership aims to transform Alzheimer's diagnostics by combining cutting-edge biomarkers and AI technology.

Circular Genomics has announced the addition of Dr. Henrik Zetterberg to its Scientific Advisory Board, aiming to enhance Alzheimer's diagnosis through innovative biomarkers.

Circular Genomics has secured exclusive IP licenses from top research institutions to boost their innovative circRNA blood test for Alzheimer's disease, aimed at improving early diagnosis.

Circular Genomics announces the appointment of distinguished experts Michael Weiner and Timothy Hohman to its Scientific Advisory Board. This move aims to enhance advancements in Alzheimer's disease diagnostics.

Circular Genomics has successfully raised $15 million to support the development of its innovative circular RNA-based platform for early Alzheimer's diagnostics.

Circular Genomics has formed a new Commercial Advisory Board to bolster its precision medicine initiatives in neurology and psychiatry. This strategic move aims to enhance market access and patient care.

Circular Genomics has appointed Phyllis Barkman Ferrell, a prominent Alzheimer's expert, to its Scientific Advisory Board to enhance its approach for psychiatric and neurological disorders.

Circular Genomics is now collaborating with Lilly Gateway Labs in San Diego to advance the use of circular RNA technologies for enhancing Alzheimer's disease diagnosis and prognosis.